

Journal of Visualized Experiments

HSV-mediated transgene expression of chimeric constructs to study behavioral function of GPCR heteromers in mice --Manuscript Draft--

Manuscript Number:	JoVE53717R3
Full Title:	HSV-mediated transgene expression of chimeric constructs to study behavioral function of GPCR heteromers in mice
Article Type:	Invited Methods Article - JoVE Produced Video
Keywords:	serotonin 5-HT2A receptor Glutamate mGlu2 mGlu3 mGlu2/3 LSD hallucinogens schizophrenia G protein-coupled receptor GPCR schizophrenia
Manuscript Classifications:	8.1.158.610: Neurosciences; 8.1.158.610.208: Neuropharmacology; 8.1.158.703: Pharmacology
Corresponding Author:	Javier Gonzalez-Maeso, PhD Icahn School of Medicine at Mount Sinai New York, NY UNITED STATES
Corresponding Author Secondary Information:	
Corresponding Author E-Mail:	javier.gonzalez-maeso@vcuhealth.org
Corresponding Author's Institution:	Icahn School of Medicine at Mount Sinai
Corresponding Author's Secondary Institution:	
First Author:	Terrell Holloway
First Author Secondary Information:	
Other Authors:	Terrell Holloway Jose L Moreno
Order of Authors Secondary Information:	
Abstract:	<p>The heteromeric receptor complex between 5-HT2A and mGlu2 has been implicated in some of the behavioral phenotypes in mouse models of psychosis^{1,2}. Consequently, investigation of structural details of the interaction between 5-HT2A and mGlu2 affecting schizophrenia-related behaviors represents a powerful translational tool. As previously shown, the head-twitch response (HTR) in mice is elicited by hallucinogenic drugs and this behavioral response is absent in 5-HT2A knockout (KO) mice^{3,4}. Additionally, by conditionally expressing the 5-HT2A receptor only in cortex, it was demonstrated that 5-HT2A receptor-dependent signaling pathways on cortical pyramidal neurons are sufficient to elicit head-twitch behavior in response to hallucinogenic drugs³. Finally, it has been shown that the head-twitch behavioral response induced by the hallucinogens DOI and lysergic acid diethylamide (LSD) is significantly decreased in mGlu2-KO mice⁵. These findings suggest that mGlu2 is at least in part necessary for the 5-HT2A receptor-dependent psychosis-like behavioral effects induced by LSD-like drugs. However, this does not provide evidence as to whether the 5-HT2A-mGlu2 receptor complex is necessary for this behavioral phenotype. To address this question, herpes simplex virus (HSV) constructs to express</p>

	either mGlu2 or mGlu2ΔTM4N (mGlu2/mGlu3 chimeric construct that does not form the 5-HT2A-mGlu2 receptor complex) in the frontal cortex of mGlu2-KO mice were used to examine whether this GPCR heteromeric complex is needed for the behavioral effects induced by LSD-like drugs ⁶ .
Author Comments:	
Additional Information:	
Question	Response
If this article needs to be filmed by a certain date to due to author/equipment/lab availability, please indicate the date below and explain in your cover letter.	
If this article needs to be "in-press" by a certain date to satisfy grant requirements, please indicate the date below and explain in your cover letter.	

TITLE:

HSV-mediated transgene expression of chimeric constructs to study behavioral function of GPCR heteromers in mice

AUTHORS AND AFFILIATION:

Holloway, Terrell
Department of Psychiatry
Icahn School of Medicine at Mount Sinai
New York, New York 10029, United States.
Email: Terrell.Holloway@icahn.mssm.edu

Moreno, Jose L.
Department of Psychiatry
Icahn School of Medicine at Mount Sinai
New York, New York 10029, United States
Email: Jose.Moreno@mssm.edu

González-Maeso, Javier
Department of Psychiatry
Department of Neurology
Friedman Brain Institute
Icahn School of Medicine at Mount Sinai
New York, New York 10029, United States

Department of Physiology and Biophysics
Virginia Commonwealth University Medical School
Richmond, Virginia 23298, United States
E-mail: jgmaeso@vcu.edu

CORRESPONDING AUTHOR:

González-Maeso, Javier
Department of Physiology and Biophysics
Virginia Commonwealth University Medical School
Richmond, Virginia 23298, United States
E-mail: jgmaeso@vcu.edu

KEYWORDS:

Virus-Mediated Gene Transfer; G protein-coupled receptor (GPCR), heteromer, lysergic acid diethylamide (LSD), (\pm)-1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane hydrochloride (DOI), hallucinogens, schizophrenia, head-twitch response (HTR).

SHORT ABSTRACT:

This article describes how to inject viral vectors into the mouse frontal cortex to test behavioral assays that require GPCR heteromeric formation.

LONG ABSTRACT:

The heteromeric receptor complex between 5-HT_{2A} and mGlu2 has been implicated in some of the behavioral phenotypes in mouse models of psychosis^{1,2}. Consequently, investigation of structural details of the interaction between 5-HT_{2A} and mGlu2 affecting schizophrenia-related behaviors represents a powerful translational tool. As previously shown, the head-twitch response (HTR) in mice is elicited by hallucinogenic drugs and this behavioral response is absent in 5-HT_{2A} knockout (KO) mice^{3,4}. Additionally, by conditionally expressing the 5-HT_{2A} receptor only in cortex, it was demonstrated that 5-HT_{2A} receptor-dependent signaling pathways on cortical pyramidal neurons are sufficient to elicit head-twitch behavior in response to hallucinogenic drugs³. Finally, it has been shown that the head-twitch behavioral response induced by the hallucinogens DOI and lysergic acid diethylamide (LSD) is significantly decreased in mGlu2-KO mice⁵. These findings suggest that mGlu2 is at least in part necessary for the 5-HT_{2A} receptor-dependent psychosis-like behavioral effects induced by LSD-like drugs. However, this does not provide evidence as to whether the 5-HT_{2A}-mGlu2 receptor complex is necessary for this behavioral phenotype. To address this question, herpes simplex virus (HSV) constructs to express either mGlu2 or mGlu2ΔTM4N (mGlu2/mGlu3 chimeric construct that does not form the 5-HT_{2A}-mGlu2 receptor complex) in the frontal cortex of mGlu2-KO mice were used to examine whether this GPCR heteromeric complex is needed for the behavioral effects induced by LSD-like drugs⁶.

INTRODUCTION:

Hallucinogens, such as LSD, psilocybin and mescaline cause significant changes in human consciousness, cognition and emotion⁷⁻⁹. Inactivation of serotonin 5-HT_{2A} receptor signaling by either genetic or pharmacological approaches causes markedly attenuated behavioral responses to hallucinogens in both rodent models^{3,10} and humans¹¹. Although hallucinogens bind other receptor subtypes⁸, the 5-HT_{2A} receptor is considered as necessary for the unique behavioral activity of these chemicals.

Group II metabotropic glutamate receptors (i.e., mGlu2 and mGlu3) have been the target of considerable attention regarding the molecular mechanism of hallucinogens and their integral role underlying psychosis¹². Previously, it has been demonstrated that mice with no expression of mGlu2 protein (mGlu2-KO mice) are insensitive to the cellular and behavioral effects of hallucinogens⁵. It has also been suggested that the 5-HT_{2A} and the mGlu2 receptors form a specific heteromeric complex through which serotonin and glutamate ligands modulate the pattern of G protein coupling in living cells^{1,2}.

Structurally, transmembrane (TM) domains 4 and 5 of mGlu2 play a fundamental role in heteromeric formation with the 5-HT_{2A} receptor⁵. Additionally, further investigation demonstrated that three residues located at the intracellular end of TM4 of mGlu2 are necessary to form the 5-HT_{2A}-mGlu2 receptor heterocomplex in living cells⁶.

Based on these findings observed in heterologous expression systems, here we describe the use of HSV-mediated expression of wild-type mGlu2 and mGlu2/mGlu3 chimeric constructs in the frontal cortex of mGlu2-KO mice to test whether heteromeric

formation between 5-HT_{2A} and mGlu2 is necessary for the head-twitch behavior induced by hallucinogenic 5-HT_{2A} receptor agonists.

PROTOCOL:

NOTE: All procedures for animal breeding and cares were conducted according to the Institutional Review Board (IRB) regulation of Icahn School of Medicine at Mount Sinai.

1. Drug and Virus Preparation

1.1. Drug Preparation

1.1.1. Prepare 15.0 ml ketamine/xylazine anesthetic by dissolving 1.35 ml of 100 mg/ml Ketamine and 0.75 ml of 20 mg/ml xylazine in 12.9 mL of 0.9% Saline solution. Thoroughly mix solution.

1.2. Virus Preparation

1.2.1. Clone the mGlu2 and mGlu2ΔTM4N constructs into a bicistronic herpes simplex virus (HSV) vector following standard protocols previously described⁶. Package the viral particles as previously described^{6,13,14}. Substitution of residues Ala-677^{4.40}, Ala-681^{4.44} and Ala685^{4.48} in mGlu2 for Ser686^{4.40}, Phe690^{4.44} and Gly-694^{4.48} in mGlu3 (HA-mGlu2ΔTM4N) have been described previously⁶. NOTE: It was previously demonstrated that the chimeric construct HA-mGlu2ΔTM4N is expressed at the plasma membrane with intact G protein-dependent signaling⁶.

1.2.2. Store viral vectors in -80 °C when not in use. Thaw viral vector on ice, and then aliquot into 10 µl aliquots. For the surgical procedure, keep on ice.

2. Surgery

2.1. Surgery Preparation

2.1.1. Weigh mouse and inject mouse with appropriate dose of ketamine/xylazine cocktail (for details, see 1.1.1).

2.1.2. Check mouse to see if properly anesthetized, squeeze foot and tail for pain response, if unable to elicit a response, the mouse is properly anesthetized.

2.1.3. Shave mouse head from the base of the skull to the tip of the nose using clippers. Apply ophthalmic gel to the mouse afterward to prevent blindness of the mouse.

2.1.4. Load each syringe onto the stereotaxic frame. Then tilt perpendicular portion of each arm of the stereotaxic frame so that they are 10 degrees away from the normal. Ensure that the arms are tilted, such that the needles are facing each other.

2.1.5. Clean each syringe by filling the needle with 70% ethanol. Fill the needle at least three times to ensure that the syringe is clean.

2.1.6. Once the needle has been cleaned, flush the needle by filling the needle with double distilled H₂O. Once flushed, fill each needle with 1.3 µl of double distilled H₂O. Twist the plunger of the syringe to release 0.3uL of double distilled H₂O. If water beads

at the tip of the needle, carefully wipe away water. If nothing comes out of the syringe, push the plunger completely down and then repeat cleaning of syringe.

2.1.7. After filling with water, then pull up the syringe filling the syringe with 0.5 µl of air.

2.1.8. Once the air and water are in the syringe, carefully fill the syringe with 1.3 µl of virus solution. At this point ensure that the total volume in the syringe is 2.8 µl. Again twist the tip of the syringe to release 0.3 µl of virus. If liquid beads at the tip of the needle, carefully wipe away liquid. If nothing comes out of the syringe, push the plunger completely down and then repeat cleaning of syringe.

2.2. Surgery

2.2.1. Attach the mouse to the stereotaxic frame, making sure to adjust the stereotaxic frame so that the skull is level and flat. Apply povidone-iodine to the exposed scalp. Using a scalpel, make a sagittal incision along the midline of the skull within the exposed shaved area. Then attach the buret clamps to the skin at the incision site to make sure that the skull remains exposed.

2.2.2. Use H₂O₂ to dissolve away the periosteum to expose the sutures of the skull. Now that the bregma and sutures are visible, be sure to adjust the stereotaxic frame to make sure that the skull is level.

2.2.3. Align the needle tips of the syringes with the bregma and record the coordinates of the bregma. Calculate the coordinates of where the needles are going to be inserted.

2.2.3.1 For the Rostral-Caudal (R-C) plane, add 1.6 mm to the recorded R-C bregma coordinates (+1.6 from Bregma). For the Dorsal-Ventral (D-V) plane, subtract 2.4 mm from the recorded D-V bregma coordinates (-2.4 from Bregma).

2.2.3.2 Finally, for the Medial Lateral (M-L) plane, add 2.6 mm to the recorded M-L bregma coordinates (+2.6 from Bregma). For all coordinates be sure to record both left and right coordinates, as this is a bilateral injection.

2.2.4. Bring the needles to the desired coordinates. Mark the places of where the needles are going to be inserted and with a drill, drill the marked areas.

2.2.5. With a cotton tip applicator wipe away any excess blood or bone fragment.

2.2.6. Bring the needles to the skull where the tips of the needles are touching the surface of the brain. Then lower the needles to the desired coordinates slowly lowering them.

2.2.7. Once the needles are at the desired coordinates, slowly inject the contents of the syringe by twisting the plunger of the needle 0.1 µl per minute over the course of 5 minutes (in total 0.5 µl).

2.2.8. Once the injection has been made leave the syringe in cortex for another 5 minutes.

2.3. Closing Up/Care

2.3.1. Remove the needles from the mouse cortex steadily and slowly. Then remove the mouse from the stereotaxic frame.

2.3.2. Apply cyanoacrylate (dermal adhesive) to the base flaps of skin from the incision and then with forceps grab the flaps of skin and place them together.

2.3.3. Allow the cyanoacrylate to dry. Place the mouse in cage over a heating pad (heating pad is optional if the surgical suite is kept under room temperature of 37°C – otherwise not necessary). Be sure to place the mouse on a paper towel to make sure that bedding does not adhere to surgical site.

2.3.4. Depending on the length of the surgical procedure, ensure that the mice is out of anesthesia within 30-60 minutes after procedure. Once the mouse has come out of anesthesia, place the mouse in an individually housed cage with some chow tabs on the floor of the cage. Monitor for recovery.

3. Head Twitch Response Experiment

3.1. Set-up

3.1.1. Carry out all behavioral testing between 10:00 AM and 2:00 PM, 2-3 days after stereotactic injection of viral particles.

3.1.2. Dissolve (\pm)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane hydrochloride (DOI) into a 0.9% saline solution to 2.0 mg/kg. Also prepare a 0.9% saline solution.

3.1.3. Prepare a home cage (28 × 18 × 15 cm) without any bedding and using a tri-pod, adjust a camera so that the view of the video camera is directly above the home cage.

3.1.4. Habituate the mice to the room for at least 4 hours prior to the beginning of the experiment.

3.1.5 Set up a camcorder to record the head twitch.

3.2. Experiment

3.2.1. Position the camera so that it is directly over a home cage. Calibrate the camera so that the entire home cage is in the field of view.

3.2.2 Weigh mouse and inject mouse intraperitoneally with appropriate dose of either 0.9% saline or DOI (0.01 ml/gr).NOTE: If a mouse weighs 25 grams, administer dose to a total volume of 0.25 ml.

3.2.3. Place each mouse back in their home cage for 10 minutes. After 10 minutes, place mouse into the center of the empty home cage and validate that there are no blind spots in the field of view of the camera. Press record on the camcorder. Leave the room. NOTE: Mouse movements and various behavioral responses therein (head twitch, ear scratch, etc. Please refer to supplemental data table 1 of Gonzalez-Maeso et al. 2007 for full list of behavioral responses induced by DOI.)³, will be recorded for 30 minutes. Therefore, it is important there are no blind spots in the field of view recorded.

3.2.4. After 30 minutes stop recording on the camcorder and place mouse back in original home cage. Repeat this process for each mouse.

3.3. Review

3.3.1. Have each referee review the tapes blind to the experimental conditions of mouse (i.e. drugs used during head twitch experiment or virus used during intracranial injection)). Manually record every head twitch throughout the video. NOTE: Head-twitch is defined as a rapid shaking head movement conducted by a mouse (supplemental video).

3.3.2. For each mouse, average the final HTR response from the three totals of the blind referees. Then group these values by experimental condition and carry out statistical analysis (i.e. t-test or ANOVA).

REPRESENTATIVE RESULTS:

Previous findings demonstrate that the head-twitch murine behavioral response is reliably and robustly elicited by hallucinogens, and it is absent in 5-HT_{2A}-KO mice³. Furthermore, it has been shown that the head-twitch response elicited by the hallucinogenic 5-HT_{2A} agonists DOI and LSD was significantly decreased in mGlu2-KO mice⁵. However, although previous findings convincingly demonstrate that 5-HT_{2A} and mGlu2 are assembled as a heteromeric complex in vitro in transfected cells^{1,2,15}, whether this structural arrangement behaves as such in living mice remained unsolved. To fully understand the role of the 5-HT_{2A}-mGlu2 receptor heterocomplex in the psychoactive-like effects induced by hallucinogenic 5-HT_{2A} receptor agonists, expression of either mGlu2 or mGlu2ΔTM4N in frontal cortex of mGlu2-KO mice to examine whether this manipulation regulates behavior.

Mice received intra-frontal cortical injections of bicistronic HSV expressing green fluorescent protein (GFP) and either mGlu2 or mGlu2ΔTM4N, or GFP alone. First, it was confirmed that the virus over-expresses mGlu2 or mGlu2ΔTM4N in mouse frontal cortex (Figs. 1A and 1B). As previously demonstrated⁵, head-twitch behavior induced by DOI was absent in mGlu2-KO mice injected with the empty vector HSV-GFP. Notably, the head-twitch response induced by the hallucinogenic 5-HT_{2A} agonist DOI was rescued in mGlu2-KO mice over-expressing mGlu2, but not mGlu2ΔTM4N, in frontal cortex as compared to that seen in animals expressing GFP (Fig. 1C). Together, these findings suggest that the 5-HT_{2A}-mGlu2 receptor complex in frontal cortex is critical for regulating psychosis-like states.

FIGURE LEGENDS:

Figure 1. Expression of mGlu2 as a receptor heterocomplex

Expression of mGlu2 as a receptor with 5-HT_{2A} is necessary for psychosis-like behavior induced by hallucinogenic drugs. A) Representative image of HSV-mediated transgene expression in frontal cortex. HSV-mGlu2, which also expresses GFP, was injected into frontal cortex, and GFP expression was revealed by immunocytochemistry, scale bar, 200-um. B) HSV-mediated transgene expression in mouse frontal cortex of mGlu2-KO mice, and anti-mGlu2 reactivity was measured by Western Blotting. Specificity of the primary antibody against the mGlu2 receptor has previously been confirmed in knockout mice⁶. Metabotropic glutamate receptors are GPCRs that form covalently linked homodimers. We measured immunoreactivity of mGlu2 as a monomer (~100 kDa)⁶. C) Viral-mediated expression of mGlu2, but not mGlu2ΔTM4N, in frontal cortex of mGlu2-KO mice significantly rescues the head-twitch response induced by the hallucinogenic 5-HT_{2A} agonist DOI (n = 4 per group). ***p < 0.001; n.s, not significant; Bonferroni's post hoc test of one-way ANOVA. Error bars represent S.E.M. Figure was modified from Moreno et al (2012)⁶.

Supplemental Video 1. Head Twitch Response.

CD-1 WT mice were injected with 2.0 mg/kg DOI and placed in a cage (wall blacked out between the two cages) to elicit head-twitch response (behavior elicited after *).

DISCUSSION:

Together with previous findings in mGlu2-KO mice⁵, the results with mGlu2 and mGlu2/mGlu3 chimeric constructs that do not form the 5-HT_{2A}-mGlu2 receptor complex in cultured cells suggest that the 5-HT_{2A}-mGlu2 heteromeric receptor complex in mouse frontal cortex is needed to induce head-twitch behavior by LSD-like hallucinogenic 5-HT_{2A} receptor agonists. A limitation of this method is that it does not measure close molecular proximity at a subcellular level in native tissue. In addition, there are various critical points to be noted. Because the mice are injected with a HSV viral vector, the time frame that the experiments to be performed are 2-4 days after injection. The location and expression of the viral vectors should be verified with immunofluorescence staining of sectioned brain no more than 4 days after the initial injection. Mice in which the coordinates do not match or do not express the viral vector should be excluded from the experimental data as they do not express the mGlu2 or mGlu2ΔTM4N. Care after stereotactic surgery is also crucial, as improper closing of the head wound can lead to infection which can cause issues in both the in vivo experiments and the immunofluorescence staining. Lastly, after stereotactic injection any behavioral paradigm (open field, alternating t-test, etc.) can be used as long as it is within the 2-4 after injection of viral particles. Again, coordinates and expression should be confirmed by immunofluorescence.

The concept that GPCRs function as homo- and/or heteromers in living cells is now well established¹⁶⁻¹⁸. However, despite some progress, more studies are needed to define the precise role(s) of GPCR heteromeric complexes in whole animal models¹⁹. Approaches such as BRET and/or FRET imaging to investigate protein-protein physical proximity within deep tissues of small animal models may provide means to enhance

the understanding of the functional role of GPCR heteromers in living subjects²⁰. Using HSV-mediated expression of GPCRs either native or with modified transmembrane proteins, provide an in vivo model to evaluate the function and interaction of GPCRs.

Further studies in rodent models are also needed to examine the stability and life- time (formation and dissociation) of GPCR heteromers²¹⁻²³, structural rearrangements between their components²⁴, and potential G protein coupling after receptor internalization^{25,26}. Given the fundamental role of GPCRs in cell signaling and function, it seems likely that this area might lead to interesting basic and translational studies.

Although further investigation is required to quantitatively characterize the ultrastructural co-localization of both receptors in human and mouse CNS, together with previous studies that convincingly demonstrate the electrophysiological, cellular, and behavioral responses induced by hallucinogens in mouse models are intrinsic to 5-HT_{2A} receptor-expressing cortical pyramidal neurons^{3,27,28}, the findings obtained using the HSV-mediated expression approach described here suggest that heteromeric formation between 5-HT_{2A} and mGlu2 receptors in mouse frontal cortex is needed for the head-twitch psychosis-like behavior induced by the hallucinogenic 5-HT_{2A} receptor agonist DOI.

HSV-mediated expression of mGlu2, but not mGlu2ΔTM4N, in frontal cortical neurons of mGlu2-KO mice rescues the head-twitch behavior induced by the hallucinogenic 5-HT_{2A} receptor agonist DOI. This translational tool might be advantageous for preclinical studies to evaluate behavioral phenotypes of GPCR heteromers.

ACKNOWLEDGEMENTS:

NIH R01 MH084894 participated in the funding of this study.

DISCLOSURES:

The authors have nothing to disclose.



REFERENCES:

- 1 Fribourg, M. *et al.* Decoding the Signaling of a GPCR Heteromeric Complex Reveals a Unifying Mechanism of Action of Antipsychotic Drugs. *Cell*. **147** (5), 1011-1023, doi:S0092-8674(11)01272-4 [pii] 10.1016/j.cell.2011.09.055, (2011).
- 2 Gonzalez-Maeso, J. *et al.* Identification of a serotonin/glutamate receptor complex implicated in psychosis. *Nature*. **452** (7183), 93-97, doi:nature06612 [pii]10.1038/nature06612, (2008).
- 3 Gonzalez-Maeso, J. *et al.* Hallucinogens Recruit Specific Cortical 5-HT(2A) Receptor-Mediated Signaling Pathways to Affect Behavior. *Neuron*. **53** (3), 439-452 (2007).
- 4 Gonzalez-Maeso, J. *et al.* Transcriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex. *J Neurosci*. **23** (26), 8836-8843 (2003).


- 5 Moreno, J. L., Holloway, T., Albizu, L., Sealfon, S. C. & Gonzalez-Maeso, J. Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT_{2A} receptor agonists. *Neurosci Lett.* **493** (3), 76-79, doi:S0304-3940(11)00092-9 [pii] 10.1016/j.neulet.2011.01.046, (2011).
- 6 Moreno, J. L. *et al.* Identification of Three Residues Essential for 5-HT_{2A}-mGlu2 Receptor Heteromerization and its Psychoactive Behavioral Function. *J Biol Chem.* **287** 44301-44319, doi:M112.413161 [pii]10.1074/jbc.M112.413161, (2012).
- 7 Geyer, M. A. & Vollenweider, F. X. Serotonin research: contributions to understanding psychoses. *Trends Pharmacol Sci.* **29** (9), 445-453 (2008).
- 8 Nichols, D. E. Hallucinogens. *Pharmacol Ther.* **101** (2), 131-181 (2004).
- 9 Hanks, J. B. & Gonzalez-Maeso, J. Animal models of serotonergic psychedelics. *ACS Chem Neurosci.* **4** (1), 33-42, doi:10.1021/cn300138m, (2013).
- 10 Fiorella, D., Rabin, R. A. & Winter, J. C. Role of 5-HT_{2A} and 5-HT_{2C} receptors in the stimulus effects of hallucinogenic drugs. II: Reassessment of LSD false positives. *Psychopharmacology (Berl).* **121** (3), 357-363 (1995).
- 11 Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F., Babler, A., Vogel, H. & Hell, D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. *Neuroreport.* **9** (17), 3897-3902 (1998).
- 12 Moreno, J. L., Sealfon, S. C. & Gonzalez-Maeso, J. Group II metabotropic glutamate receptors and schizophrenia. *Cell Mol Life Sci.* **66** (23), 3777-3785, doi:10.1007/s00018-009-0130-3, (2009).
- 13 Kurita, M. *et al.* HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity. *Nat Neurosci.* **15** (9), 1245-1254, doi:nn.3181 [pii]10.1038/nn.3181, (2012).
- 14 Kurita, M. *et al.* Repressive Epigenetic Changes at the mGlu2 Promoter in Frontal Cortex of 5-HT_{2A} Knockout Mice. *Mol Pharmacol.* **83** (6), 1166-1175, doi:mol.112.084582 [pii]10.1124/mol.112.084582, (2013).
- 15 Rives, M. L. *et al.* Crosstalk between GABAB and mGlu1a receptors reveals new insight into GPCR signal integration. *Embo J.* **28** (15), 2195-2208, doi:emboj2009177 [pii]10.1038/emboj.2009.177, (2009).
- 16 Milligan, G. The Prevalence, Maintenance and Relevance of GPCR Oligomerization. *Mol Pharmacol.* **Epub ahead of print** (84), 158-169, doi:mol.113.084780 [pii]10.1124/mol.113.084780, (2013).
- 17 Ferre, S. *et al.* G protein-coupled receptor oligomerization revisited: functional and pharmacological perspectives. *Pharmacol Rev.* **66** (2), 413-434, doi:66/2/413 [pii]10.1124/pr.113.008052, (2014).
- 18 Gonzalez-Maeso, J. GPCR oligomers in pharmacology and signaling. *Mol Brain.* **4** (1), 20, doi:1756-6606-4-20 [pii]10.1186/1756-6606-4-20, (2011).
- 19 Gonzalez-Maeso, J. Family a GPCR heteromers in animal models. *Front Pharmacol.* **5** 226, doi:10.3389/fphar.2014.00226, (2014).
- 20 Dragulescu-Andrasi, A., Chan, C. T., De, A., Massoud, T. F. & Gambhir, S. S. Bioluminescence resonance energy transfer (BRET) imaging of protein-protein interactions within deep tissues of living subjects. *Proceedings of the National Academy of Sciences of the United States of America.* **108** (29), 12060-12065 (2011).

- 21 Calebiro, D. *et al.* Single-molecule analysis of fluorescently labeled G-protein-coupled receptors reveals complexes with distinct dynamics and organization. *Proc Natl Acad Sci U S A.* **110** (2), 743-748, doi:1205798110 [pii]10.1073/pnas.1205798110, (2013).
- 22 Fonseca, J. M. & Lambert, N. A. Instability of a class a G protein-coupled receptor oligomer interface. *Mol Pharmacol.* **75** (6), 1296-1299, doi:mol.108.053876 [pii]10.1124/mol.108.053876, (2009).
- 23 Hern, J. A. *et al.* Formation and dissociation of M1 muscarinic receptor dimers seen by total internal reflection fluorescence imaging of single molecules. *Proc Natl Acad Sci U S A.* **107** (6), 2693-2698, doi:0907915107 [pii]10.1073/pnas.0907915107, (2010).
- 24 Hlavackova, V. *et al.* Sequential inter- and intrasubunit rearrangements during activation of dimeric metabotropic glutamate receptor 1. *Sci Signal.* **5** (237), ra59, doi:5/237/ra59 [pii]10.1126/scisignal.2002720, (2012).
- 25 Irannejad, R. *et al.* Conformational biosensors reveal GPCR signalling from endosomes. *Nature.* **495** (7442), 534-538, doi:nature12000 [pii]10.1038/nature12000, (2013).
- 26 Calebiro, D., Nikolaev, V. O., Persani, L. & Lohse, M. J. Signaling by internalized G-protein-coupled receptors. *Trends Pharmacol Sci.* **31** (5), 221-228, doi:S0165-6147(10)00014-3 [pii]10.1016/j.tips.2010.02.002, (2010).
- 27 Celada, P., Puig, M. V., Diaz-Mataix, L. & Artigas, F. The hallucinogen DOI reduces low-frequency oscillations in rat prefrontal cortex: reversal by antipsychotic drugs. *Biol Psychiatry.* **64** (5), 392-400, doi:S0006-3223(08)00336-3 [pii]10.1016/j.biopsych.2008.03.013, (2008).
- 28 Béïque, J.-C., Imad, M., Mladenovic, L., Gingrich, J. A. & Andrade, R. Mechanism of the 5-hydroxytryptamine 2A receptor-mediated facilitation of synaptic activity in prefrontal cortex. *Proceedings of the National Academy of Sciences of the United States of America.* **104** (23), 9870-9875 (2007).

A **B**



C



Name of Material/ Equipment	Company	Catalog Number
mGlu2 bicitronic herpes simplex virus (HSV) vector	MIT Core	
mGlu2ΔTM4N bicitronic herpes simplex virus (HSV) vector	MIT Core	
GFP bicitronic herpes simplex virus (HSV) vector	MIT Core	
		List no. 4811-
		20ml, NADA #139-
		236, NDC Code(s):
xylazine	Lloyd	61311-481-10
		KetaVed-10ml,
		NADA #200-029,
		NDC Code(s):
ketamine	Vedco	50989-161-06
	Fisher	
ophthalmic gel	Scientific	NC0550805
	Fisher	
burret clips	Scientific	NC9268369
	Fisher	
Feather surgical blade	Scientific	NC9032736
	Fisher	
Hydrogen Peroxide	Scientific	19-898-919
	Fisher	
Hamilton syringe	Scientific	14815203
	Fisher	
Hamilton™ Small Hub Removable Needles (33 Ga)	Scientific	14816206
	Fisher	
Cordless Micro Drill	Scientific	NC9089241
	Fisher	
Dermabond Dermal Adhesive	Scientific	NC0690470

(±)-1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane hydrochlor Aldrich Sigma- 42203-78-1

Comments/Description

mGlu2 and mGlu2DTM4N were subcloned into the bicistronic HSV-GFP virus vector p1005+ HSV expressing GFP under the control of the CMV promoter.
mGlu2 and mGlu2DTM4N were subcloned into the bicistronic HSV-GFP virus vector p1005+ HSV expressing GFP under the control of the CMV promoter.
mGlu2 and mGlu2DTM4N were subcloned into the bicistronic HSV-GFP virus vector p1005+ HSV expressing GFP under the control of the CMV promoter.

1.35 mL of 100mg/ml of ketamine+.75 mL of 20mg/ml of xylazine are diluted in 12.0 mL of .9% saline solution

1.35 mL of 100mg/ml of ketamine+.75 mL of 20mg/ml of xylazine are diluted in 12.0 mL of .9% saline solution

Dissolved in .9% saline solution to the concentration of 2.0 mg/kg

- . Viral particles were produced by the Viral Core Facility at the McGovern Institute (MIT). For more information, please contact the director, Dr. R.
- . Viral particles were produced by the Viral Core Facility at the McGovern Institute (MIT). For more information, please contact the director, Dr. R.
- . Viral particles were produced by the Viral Core Facility at the McGovern Institute (MIT). For more information, please contact the director, Dr. R.

achael Neve (rneve@mit.edu)

achael Neve (rneve@mit.edu)

achael Neve (rneve@mit.edu)



[Click here to access/download](#)

Animated Figure (video and/or .ai figure files)
HeadTwitchResponse.wmv



1 Alewife Center #200
Cambridge, MA 02140
tel. 617.945.9051
www.jove.com

ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:

HSV-mediated herpes repress- of d. me.

Author(s):

Terrill Hollman, Jose C. Moore, J. Elizabeth Hays

Item 1 (check one box): The Author elects to have the Materials be made available (as described at <http://www.jove.com/publish>) via: ☒ Standard Access ☐ Open Access

Item 2 (check one box):



The Author is NOT a United States government employee.



The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.



The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: "**Agreement**" means this Article and Video License Agreement; "**Article**" means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; "**Author**" means the author who is a signatory to this Agreement; "**Collective Work**" means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; "**CRC License**" means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; "**Derivative Work**" means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; "**Institution**" means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; "**JoVE**" means MyJoVE Corporation, a Massachusetts corporation and the publisher of *The Journal of Visualized Experiments*; "**Materials**" means the Article and / or the Video; "**Parties**" means the Author and JoVE; "**Video**" means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4 and 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the "Open Access" box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

ARTICLE AND VIDEO LICENSE AGREEMENT

4. **Retention of Rights in Article.** Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. **Grant of Rights in Video – Standard Access.** This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. **Grant of Rights in Video – Open Access.** This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this Section 6 is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. **Government Employees.** If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum rights permitted under such

statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. **Likeness, Privacy, Personality.** The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

9. **Author Warranties.** The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

10. **JoVE Discretion.** If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have

ARTICLE AND VIDEO LICENSE AGREEMENT

full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

11. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's

expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

12. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

13. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement required per submission.

CORRESPONDING AUTHOR:

Name:

Jana Gonzalez - Haess

Department:

Biology

Institution:

St. George's School

Article Title:

MS-mediated home expression

Signature:

[Signature]

Date:

05/15/15

Please submit a signed and dated copy of this license by one of the following three methods:

- 1) Upload a scanned copy of the document as a pdf on the JoVE submission site;
- 2) Fax the document to +1.866.381.2236;
- 3) Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02139

For questions, please email submissions@jove.com or call +1.617.945.9051

Editorial comments:

1. Long abstract focuses on results/findings and should instead focus on the method.
We think that the complexity of the concept of GPCR heteromeric expression and function needs to be included in the abstract in order to make the abstract itself coherent, logical and intelligible. Without this background the main goal of the method would be trivial since it has been published and validated previously with other goals.
2. JoVE is unable to publish manuscripts containing commercial sounding language, including trademark or registered trademark symbols (TM/R) and the mention of company brand names before an instrument or reagent. Please remove all commercial sounding language from your manuscript and replace it with a more generic term as much as possible throughout the entire manuscript. All commercial products should be sufficiently referenced in the table of materials/reagents. Examples of commercial sounding language in your manuscript are betadine, etc.
Corrected.
3. Please provide more details in section 3.2
Corrected.
4. What is being calibrated besides the field of view?
The field of view is the only thing being calibrated on the camera. This was further clarified in the manuscript.
5. Please avoid using pronouns in the protocol section. Search for you, your, we, I etc.
Corrected.
6. Ensure that the steps are in imperative tense.
Corrected.
7. In step 3.2.2. "Please specify various stereotypy therein such as...." Please clarify or give more details.
I have provided examples and have referenced the paper listing the various stereotypies found following an injection with DOI.
8. In step 3.2.2. Please begin "it is important that there..." as a new sentence.
Corrected.
9. In step 3.3.2, what statistical analysis are carried out? Please specify.
Depending on the number of groups the statistical analysis carried out was a t-test or ANOVA. This is also clarified in the manuscript.
10. In the discussion section, please discuss critical steps and potential modifications/troubleshooting of this protocol.
Corrected.
- 11.
12. Please take this opportunity to thoroughly proofread the manuscript to ensure that there are no spelling or grammar issues. The JoVE editor will not copy-edit your manuscript and any errors in the submitted revision may be present in the published version.



Click here to access/download

Supplemental code file (if applicable)
renamed_fff19.pdf

